Immunic secures $400M to support late-stage MS trials - ICYMI

Core Viewpoint - Immunic Inc has secured up to $400 million in private placement financing to support late-stage trials and prepare for the potential commercial launch of vidofludimus calcium for multiple sclerosis [1][2]. Financing Details - The financing is described as a transformative transaction, with $200 million already received and the remainder available in a second tranche [2][4]. - This capital provides the necessary flexibility for the company to transition into a commercial-stage organization as it approaches a pivotal data milestone [2][4]. Clinical Trials and Milestones - The primary near-term catalyst is the Phase 3 ENSURE program in relapsing multiple sclerosis (RMS), which includes two twin studies [3][6]. - An interim analysis in 2024 led to a recommendation from the Independent Data Monitoring Committee to continue the trials as planned [3][6]. - Topline data from the four-year, 2,200-patient program is expected by the end of the year [3][6]. Future Plans - The financing will cover the completion of the Phase 3 studies in relapsing MS and the preparation for a New Drug Application (NDA) submission in mid-next year [5]. - The company also plans to initiate a Phase 3 study in primary progressive MS, addressing a significant unmet medical need [5].